Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 27
2014 178
2015 208
2016 137
2017 145
2018 176
2019 203
2020 181
2021 167
2022 44
Text availability
Article attribute
Article type
Publication date

Search Results

1,205 results
Results by year
Filters applied: . Clear all
Page 1
Neurological update: MOG antibody disease.
Wynford-Thomas R, Jacob A, Tomassini V. Wynford-Thomas R, et al. J Neurol. 2019 May;266(5):1280-1286. doi: 10.1007/s00415-018-9122-2. Epub 2018 Dec 19. J Neurol. 2019. PMID: 30569382 Free PMC article. Review.
Neurodevelopmental disorders.
Thapar A, Cooper M, Rutter M. Thapar A, et al. Lancet Psychiatry. 2017 Apr;4(4):339-346. doi: 10.1016/S2215-0366(16)30376-5. Epub 2016 Dec 13. Lancet Psychiatry. 2017. PMID: 27979720 Review.
Altering the course of schizophrenia: progress and perspectives.
Millan MJ, Andrieux A, Bartzokis G, Cadenhead K, Dazzan P, Fusar-Poli P, Gallinat J, Giedd J, Grayson DR, Heinrichs M, Kahn R, Krebs MO, Leboyer M, Lewis D, Marin O, Marin P, Meyer-Lindenberg A, McGorry P, McGuire P, Owen MJ, Patterson P, Sawa A, Spedding M, Uhlhaas P, Vaccarino F, Wahlestedt C, Weinberger D. Millan MJ, et al. Nat Rev Drug Discov. 2016 Jul;15(7):485-515. doi: 10.1038/nrd.2016.28. Epub 2016 Mar 4. Nat Rev Drug Discov. 2016. PMID: 26939910 Review.
COVID-19 Vaccine Response in People with Multiple Sclerosis.
Tallantyre EC, Vickaryous N, Anderson V, Asardag AN, Baker D, Bestwick J, Bramhall K, Chance R, Evangelou N, George K, Giovannoni G, Godkin A, Grant L, Harding KE, Hibbert A, Ingram G, Jones M, Kang AS, Loveless S, Moat SJ, Robertson NP, Schmierer K, Scurr MJ, Shah SN, Simmons J, Upcott M, Willis M, Jolles S, Dobson R. Tallantyre EC, et al. Ann Neurol. 2022 Jan;91(1):89-100. doi: 10.1002/ana.26251. Epub 2021 Nov 17. Ann Neurol. 2022. PMID: 34687063 Free PMC article.
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. Brown JWL, et al. JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588. JAMA. 2019. PMID: 30644981 Free PMC article.
1,205 results